The Levels of Circulating Vascular Endothelial Growth Factor and Soluble Flt-1 in Pregnancies Complicated by Preeclampsia

Overview

Journal J Korean Med Sci

Specialty General Medicine

Date 2007 Feb 14

PMID 17297258

Citations 19

Authors

Eun Sung Lee

Min-Jeong Oh

Jae Won Jung

Ji-Eun Lim

Hyun-Joo Seol

Kyung-Ju Lee

Hai-Joong Kim

Affiliations

Soon will be listed here.

Abstract

To evaluate the role of vascular endothelial growth factor (VEGF) in the pathogenesis of preeclampsia, we measured total VEGF, free VEGF and soluble Flt-1 (sFlt-1) concentrations and determined their relationships. Maternal serum samples were collected from 20 patients with preeclampsia and 20 normotensive women with uncomplicated pregnancies matched with the patients with preeclampsia for gestational age and parity. The serum concentrations of total VEGF (2.39+/-0.75 vs. 0.28+/-0.14) and sFlt-1 (934.5+/-235.5 vs. 298.0+/-161.2) were significantly increased in the patients with preeclampsia compared to the women with uncomplicated pregnancies. However the serum concentration of free VEGF (21.5+/-6.3 vs. 134.0+/-16.3) was lower in patients with preeclampsia. There was a positive correlation between the serum concentrations of total VEGF and sFlt-1 with systolic and diastolic blood pressure, respectively. There was a negative correlation between the serum concentration of free VEGF and systolic and diastolic blood pressure. There was a strong negative correlation between free VEGF and sFlt-1 concentrations. In conclusion, we found VEGF and sFlt-1 were related to the pathogenesis of preeclampsia. Although reduced concentrations of free VEGF might interfere with endothelial cell function and survival, further studies are required to clarify its specific role in the pathogenesis of preeclampsia.

Citing Articles

Systematic design and evaluation of aptamers for VEGF and PlGF biomarkers of Preeclampsia.

Mallawarachchi S, Cebecioglu R, Althumayri M, Beker L, Fernando S, Koydemir H BMC Biotechnol. 2024; 24(1):64.

PMID: 39334133 PMC: 11428563. DOI: 10.1186/s12896-024-00891-0.

Maternal angiogenic factor disruptions prior to clinical diagnosis of preeclampsia: insights from the REVAMP study.

Nema J, Sundrani D, Randhir K, Deshpande J, Lalwani S, Wagh G Hypertens Res. 2024; 47(9):2532-2548.

PMID: 38965425 DOI: 10.1038/s41440-024-01775-8.

High-throughput methylome analysis reveals differential methylation for early and late onset preeclampsia for mothers and their children.

Layman C, Ward S, Davis B, Nevonen K, Okhovat M, Rincon M Physiol Genomics. 2024; 56(3):276-282.

PMID: 38189116 PMC: 11283906. DOI: 10.1152/physiolgenomics.00058.2023.

From Biomarkers to the Molecular Mechanism of Preeclampsia-A Comprehensive Literature Review.

Rybak-Krzyszkowska M, Staniczek J, Kondracka A, Boguslawska J, Kwiatkowski S, Gora T Int J Mol Sci. 2023; 24(17).

PMID: 37686054 PMC: 10487701. DOI: 10.3390/ijms241713252.

Predictive value of the sFlt‑1/PlGF ratio in women with suspected preeclampsia: An update (Review).

Velegrakis A, Kouvidi E, Fragkiadaki P, Sifakis S Int J Mol Med. 2023; 52(4).

PMID: 37594116 PMC: 10500221. DOI: 10.3892/ijmm.2023.5292.

References

Sharkey A, Cooper J, Balmforth J, McLaren J, Clark D, Charnock-Jones D . Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies complicated by pre-eclampsia. Eur J Clin Invest. 1996; 26(12):1182-5. DOI: 10.1046/j.1365-2362.1996.830605.x. View

Polliotti B, Fry A, Saller D, Mooney R, Cox C, Miller R . Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol. 2003; 101(6):1266-74. DOI: 10.1016/s0029-7844(03)00338-7. View

Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T . Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab. 2003; 88(5):2348-51. DOI: 10.1210/jc.2002-021942. View

Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Kim Y, Goncalves L . Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol. 2004; 190(6):1541-7. DOI: 10.1016/j.ajog.2004.03.043. View

Brockelsby J, Hayman R, Ahmed A, Warren A, Johnson I, Baker P . VEGF via VEGF receptor-1 (Flt-1) mimics preeclamptic plasma in inhibiting uterine blood vessel relaxation in pregnancy: implications in the pathogenesis of preeclampsia. Lab Invest. 1999; 79(9):1101-11. View

Baker P, Krasnow J, Roberts J, Yeo K . Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia. Obstet Gynecol. 1995; 86(5):815-21. DOI: 10.1016/0029-7844(95)00259-T. View

Ferrara N, Houck K, Jakeman L, Leung D . Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992; 13(1):18-32. DOI: 10.1210/edrv-13-1-18. View

Shibuya M . Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res. 1995; 67:281-316. DOI: 10.1016/s0065-230x(08)60716-2. View

Ashworth J, Warren A, Johnson I, Baker P . Plasma from pre-eclamptic women and functional change in myometrial resistance arteries. Br J Obstet Gynaecol. 1998; 105(4):459-61. DOI: 10.1111/j.1471-0528.1998.tb10134.x. View

10.

Anthony F, Evans P, Wheeler T, Wood P . Variation in detection of VEGF in maternal serum by immunoassay and the possible influence of binding proteins. Ann Clin Biochem. 1997; 34 ( Pt 3):276-80. DOI: 10.1177/000456329703400309. View

11.

Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A . Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003; 278(15):12605-8. DOI: 10.1074/jbc.C300012200. View

12.

LEVINE R, Ewell M, Hauth J, Curet L, Catalano P, Morris C . Should the definition of preeclampsia include a rise in diastolic blood pressure of >/=15 mm Hg to a level <90 mm Hg in association with proteinuria?. Am J Obstet Gynecol. 2000; 183(4):787-92. DOI: 10.1067/mob.2000.108865. View

13.

Kupferminc M, Daniel Y, Englender T, Baram A, Many A, Jaffa A . Vascular endothelial growth factor is increased in patients with preeclampsia. Am J Reprod Immunol. 1997; 38(4):302-6. DOI: 10.1111/j.1600-0897.1997.tb00519.x. View

14.

Reuvekamp A, Poulina I, Capello J, Duits A . Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol. 1999; 106(10):1019-22. DOI: 10.1111/j.1471-0528.1999.tb08107.x. View

15.

Bhattacharjee G, Asplin I, Wu S, Gawdi G, Pizzo S . The conformation-dependent interaction of alpha 2-macroglobulin with vascular endothelial growth factor. A novel mechanism of alpha 2-macroglobulin/growth factor binding. J Biol Chem. 2000; 275(35):26806-11. DOI: 10.1074/jbc.M000156200. View

16.

Levine R, Maynard S, Qian C, Lim K, England L, Yu K . Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350(7):672-83. DOI: 10.1056/NEJMoa031884. View

17.

Brockelsby J, Anthony F, Johnson I, Baker P . The effects of vascular endothelial growth factor on endothelial cells: a potential role in preeclampsia. Am J Obstet Gynecol. 2000; 182(1 Pt 1):176-83. DOI: 10.1016/s0002-9378(00)70510-2. View

18.

Lyall F, Greer I, Boswell F, Fleming R . Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol. 1997; 104(2):223-8. DOI: 10.1111/j.1471-0528.1997.tb11050.x. View

19.

Hood J, Meininger C, Ziche M, Granger H . VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 1998; 274(3):H1054-8. DOI: 10.1152/ajpheart.1998.274.3.H1054. View

20.

Luttun A, Carmeliet P . Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered?. J Clin Invest. 2003; 111(5):600-2. PMC: 151908. DOI: 10.1172/JCI18015. View